Retour aux projets

25770.2 PFLS-LS

25770.2 PFLS-LS

Résumé

Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by Notch pathway activation to be selected for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.

Textes supplémentaires

Abstract

Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by NOTCH pathway activation, for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.

Participants

Rajwinder Lehal

Wirtschaftspartner

raj.lehal@cellestia.com

Cellestia Biotech AG CHE-162.364.457 Rajwinder Lehal Hochbergerstr. 60C 4057 Basel BS CH

Freddy Radtke

Kontaktperson

freddy.radtke@epfl.ch

EPFL SV ISREC UPRAD Life Science Faculty Freddy Radtke Station 19 1015 Lausanne VD CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2017-09-30
Date de fin
2019-09-30
Coûts totaux approuvés
CHF 654452.35
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%